Survivorship – Acute Lymphoblastic Leukemia (ALL)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

**ELIGIBILITY**

- Acute Lymphoblastic Leukemia patients
- 5 years post diagnosis, no evidence of relapse

**CONCURRENT COMPONENTS OF VISIT**

- Year 5-9, every 6 months. Then starting year 10, annually.
  - History and physical
  - CBC with differential
  - Chemistries (CMP, LDH, and uric acid)

**SURVEILLANCE**

- New primary or relapsed disease?
  - Yes
    - Return to primary treating physician
  - No
    - Continue survivorship monitoring

**MONITORING FOR LATE EFFECTS**

- Consider:
  - Pulmonary toxicity. Monitor pulmonary function tests (PFT) if patient symptomatic
  - Cardiovascular screening annually
  - Lipid panel annually
  - Immunoglobulin levels annually
  - CD4 count, if not recovered
  - Bone Health (see Breast Cancer Survivorship: Bone Health Algorithm)
  - Neuropathy screening
  - Avascular necrosis as clinically indicated
  - Assess for diabetes if indicated (late onset)

**RISK REDUCTION/ EARLY DETECTION**

- Refer or consult as indicated

**PSYCHOSOCIAL FUNCTIONING**

- See Page 2

1 Consider use of Vanderbilt’s ABCDE’s approach to cardiovascular health
Patient education, counseling and screening:
- Lifestyle risk assessment\(^1\)
- Cancer screening\(^2\)
- HPV vaccination as clinically indicated (see HPV Vaccination Algorithm)
- Screening for Hepatitis B and C as clinically indicated (see Hepatitis Screening and Management – HBV and HCV Algorithm)
- Vaccinations\(^3\) as appropriate
  - Pneumococcus vaccines PCV13 followed by PPSV23 at least 8 weeks apart. Thereafter, only PPSV23 every 5 years. Thereafter tetanus-diphtheria (Td) vaccination every 10 years.
- Influenza vaccination yearly
- Consider one dose of tetanus-diphtheria-pertussis (Tdap) vaccine as an adult if patient has not received Tdap previously and there are no contraindications. Thereafter tetanus-diphtheria (Td) vaccination every 10 years.
- Patients should inform their providers about plans to travel outside of the US at least one month in advance for appropriate counseling and vaccinations
- Recommendations for vaccination of household members

Assess for the following as clinically indicated:
- Distress management (see Distress Screening and Psychosocial Management Algorithm)
- Access to primary health care
- Vision/cataract screening (see Cataract Screening Algorithm)
- Financial stressors
- Relationship issues
- Infertility

\(^1\) See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice
\(^2\) Includes breast, cervical (if appropriate), colorectal, liver, lung, pancreatic, prostate and skin cancer screening
\(^3\) Based on Centers for Disease Control and Prevention (CDC) guidelines
SUGGESTED READINGS


Survivorship – Acute Lymphoblastic Leukemia (ALL)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This survivorship consensus algorithm is based on majority expert opinion of the Leukemia Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

- Ella Ariza Heredia, MD (Infectious Diseases)
- Naval Daver, MD (Leukemia)
- Alessandra Ferrajoli, MD (Leukemia)
- Shonice Holdman, MBA*
- Tapan Kadia, MD (Leukemia)
- Paula Lewis-Patterson, DNP, RN, NEA-BC (Cancer Survivorship)
- Jeffrey Lockett, BSN, RN*
- Michael Rytting, MD (Pediatrics – Patient Care)

* Clinical Effectiveness Development Team